4 transcripts
ABBV
Earnings call transcript
NYSE
2024 Q2
25 Jul 24
antibody. As Rob mentioned, we remain on track to close the Cerevel transaction soon, and we look forward to welcoming the team into our R&D organization
ABBV
Earnings call transcript
NYSE
2024 Q1
26 Apr 24
built an outstanding company culture, an important priority and competitive advantage. And our productive R&D engine, which has yielded numerous
ABBV
Earnings call transcript
NYSE
2023 Q4
2 Feb 24
across our industry, but has also supported continued investment in our business for long-term growth. These investments include higher adjusted R&D expense
ABBV
Earnings call transcript
NYSE
2023 Q2
27 Jul 23
President, R&D and Chief Scientific Officer. Joining us for the Q&A portion of the call is Roopal Thakkar, Senior Vice President, Development
- Prev
- 1
- Next